Navigation Links
ReBuilder Medical Technologies, Inc. Announces New York Marketing Agreement
Date:8/26/2009

CHARLES TOWN, W.Va., Aug. 26 /PRNewswire-FirstCall/ -- ReBuilder Medical Technologies, Inc. (Pink Sheets: RBRM) a provider of electronic treatments for the pain resulting from peripheral neuropathy and Peripheral Artery Disease today announced that it has signed a marketing agreement for the state of New York.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO )

More than 50,000 patients suffering from pain in their legs and feet have been helped by the ReBuilder, an electrical stimulation device that the patient administers himself in the privacy of his own home for 30 minutes a day.

"By signing this deal, we have increased our visibility in this major metropolitan market," said David Phillips, Ph.D. CEO, "and since the principals are Podiatrists, they have a natural 'in' with other doctors of Podiatric Medicine."

Additionally, Dr. Phillips reported: "We will release the name of the organization in the coming weeks when they have all their PR in place and are ready to begin their roll-out. In the meantime, if doctors in the New York area want info they can call us."

Finally, Dr. Phillips told reporters today: "We are also negotiating an agreement for the state of Tenn. with a group of Neurologists. New York may double our sales beginning in one month and we expect the same for Tennessee."

Inquiries can be made at www.rebuildermedical.com.

Safe Harbor: This letter contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to successfully implement its turnaround strategy, changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this letter will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as representation by the Company or any other person that the objectives and plans of the Company will be achieved. In assessing forward-looking statements included herein, readers are urged to carefully read those statements. When used in the Annual Report on Form 10-K, the words "estimate," "anticipate," "expect," "believe," and similar expressions are intended to be forward-looking statements.


'/>"/>
SOURCE ReBuilder Medical Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Announces First Quarter 2009 is Profitable
2. ReBuilder Medical Technologies, Inc. to Change Name to American Med Tech
3. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
4. ReBuilder Medical (RBRM) Neuropathy Market Doubles to $5 Billion
5. ReBuilder Medical Technologies, Inc. Appears Recession Proof
6. ReBuilder Medical Technologies, Inc. Says No to OTC - Rather Wait for NASDAQ
7. ReBuilder Medical Technologies, Inc. Seeks a Bigger and More Credible Equity Market - NASDAQ, here we come!
8. ReBuilder Medical Technologies, Inc. Reports 1st Quarter 2008 Sales Increase of Over 88%
9. ReBuilder Medical Technologies, Inc. Announces Top Sales Month - $410,000
10. ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years
11. ReBuilder Medical Technologies, Inc. Announces Revolutionary Electronic Zapper Said to Destroy Molluscum Contagiosum Pathogen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology: